BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q1 EPS of ($0.84), $0.16 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $194.5 million versus the consensus estimate of $178.16 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.